Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein
Achieved 86% and 93% mean serum TTR reduction by day 28 at 0.7 mg/kg and…
From Experimentation to Production – Operationalizing Enterprise AI on AWS